GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ORIC Pharmaceuticals Inc (NAS:ORIC) » Definitions » 1-Year ROIIC %

ORIC (ORIC Pharmaceuticals) 1-Year ROIIC % : 183.70% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is ORIC Pharmaceuticals 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. ORIC Pharmaceuticals's 1-Year ROIIC % for the quarter that ended in Sep. 2024 was 183.70%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for ORIC Pharmaceuticals's 1-Year ROIIC % or its related term are showing as below:

ORIC's 1-Year ROIIC % is ranked better than
82.14% of 1422 companies
in the Biotechnology industry
Industry Median: -11.235 vs ORIC: 183.70

ORIC Pharmaceuticals 1-Year ROIIC % Historical Data

The historical data trend for ORIC Pharmaceuticals's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ORIC Pharmaceuticals 1-Year ROIIC % Chart

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
Get a 7-Day Free Trial -191.47 1,811.16 -50.67 39.19 -601.38

ORIC Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -369.38 -601.38 410.84 -270.21 183.70

Competitive Comparison of ORIC Pharmaceuticals's 1-Year ROIIC %

For the Biotechnology subindustry, ORIC Pharmaceuticals's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ORIC Pharmaceuticals's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where ORIC Pharmaceuticals's 1-Year ROIIC % falls into.



ORIC Pharmaceuticals 1-Year ROIIC % Calculation

ORIC Pharmaceuticals's 1-Year ROIIC % for the quarter that ended in Sep. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -134.753 (Sep. 2024) - -101.471 (Sep. 2023) )/( 31.499 (Sep. 2024) - 49.617 (Sep. 2023) )
=-33.282/-18.118
=183.70%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


ORIC Pharmaceuticals  (NAS:ORIC) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


ORIC Pharmaceuticals 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of ORIC Pharmaceuticals's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


ORIC Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
Executives
Jacob Chacko director, officer: President and CEO C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121
Pratik S Multani officer: Chief Business Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Dominic Piscitelli officer: Chief Financial Officer C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Column Group Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group Ii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David V Goeddel 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Angie You director C/O AMUNIX PHARMACEUTICALS, INC., 2 TOWER PLACE, #1100, SOUTH SAN FRANCISCO CA 94080
Richard A. Heyman director 5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022